FAST vs NKTR · P/E 43, rev $4.59B vs rev $21.0M
Fastenal Company (FAST) versus Nektar Therapeutics (NKTR) — a side-by-side from cached financials, not a winner call.
Fastenal Company (FAST) is a industrial distribution company listed on US.
Nektar Therapeutics (NKTR) is a biotechnology company listed on US.
Latest reported FAST revenue for 2026-06-30 was $4.59B. Net income was $722.6M. FAST currently screens at market cap $49.48B and trailing P/E 43.1.
Latest reported NKTR revenue for 2026-06-30 was $21.0M. Net income was -$85.5M. Revenue was up 93.3% from 2026-03-31 to 2026-06-30. NKTR currently screens at market cap $307.2M.
FAST currently screens at market cap $49.48B and trailing P/E 43.1. NKTR currently screens at market cap $307.2M.
Not investment advice. Open the FAST and NKTR stock pages for the full models.
Not investment advice.